(CercleFinance.com) – Pherecydes Pharma dropped 6% after the precision phage therapy specialist completed a capital increase announced on February 15 on the occasion of the publication of its merger project with Erytech.
This fundraising for a total amount of 1.5 million euros was fully subscribed by Auriga IV Bioseeds, Ouest Ventures III and the pool of shareholders represented by Guy Rigaud, historical shareholders of the company.
The new shares represent 9.04% of the number of shares in circulation after the operation. The gross proceeds will primarily be used to fund its cash requirements until the planned merger is completed no later than June 30.